Luspatercept, is a medication used for the treatment of anemia in beta thalassemia and myelodysplastic syndromes. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication. Luspatercept is indicated for the treatment of adults with transfusion-dependent anemia due to very low, low and intermediate-risk myelodysplastic syndromes (MDS) with ring sideroblasts, who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy. Luspatercept is indicated for the treatment of adults with transfusion-dependent anaemia associated with beta thalassaemia.<\/p>\n
To access luspatercept-aamt for injection sold under the brand name can be made available on request to patient if the drug has not been approved or is not available in your country. For information or advice, call IPN’s Pharmaceutical Expert. Our expert will be happy to take your query and guide with an effective solution. Be free and call today for full support at +91 9891 296 838 (Mr. Tarun) \/ +91 9811 747 774 (Mr. Neeraj).<\/p>\n
Reblozyl (luspatercept-aamt for injection) for subcutaneous use Initial U.S. Approval:\u00a0 2019<\/p>\n","protected":false},"excerpt":{"rendered":"
Reblozyl (luspatercept) is a medication used for the treatment of adults with anemia (low red blood cells) associated with beta thalassemia or myelodysplastic syndromes.<\/p>\n
DISEASE INDICATIONS-Lymphoma If you have a prescription from a Registered Medical Practitioner (RMP),\u00a0IPN<\/a> in Delhi can assist you in obtaining access to genuine medication.\u00a0 Our professional will provide you with a step-by-step guide on how to legally and safely import \u201cluspatercept-aamt for injection\u201d based on the information you provide.<\/p>\n
\nDosage Forms and Strengths: \u00a0For injection: 25 mg lyophilized powder in a single-dose vial for reconstitution (3) For injection: 75 mg lyophilized powder in a single-dose vial for reconstitution.
\nMANUFACTURER-Bristol-Myers Squibb
\nUSAGE-Subcutaneous
\nMEDICINE APPROVED BY-European Medical Agency (EMA), Food and Drug Administration (FDA), Health Canada
\nSummary of FDA-approved use on approval date: Click Here<\/a>
\n(see Drugs@FDA for complete indication)<\/p>\nAccess the best support services globally<\/h4>\n